Immunicum raises 352 MSEK

16 October 2018 | 7:57 am
Carlos de Sousa
Immunicum raises SEK 351M in a directed issue and a fully guaranteed rights issue for continued clinical development of Ilixadencel – a new cancer immunotherapy. On 16 October 2018, the Board of Immunicum AB decided to implement a directed issue of approximately SEK 178M (the “Directed Issue”) and a fully guaranteed rights issue of approximately […]

Carl Borrebaeck is new member of the board at Qlucore

15 October 2018 | 12:34 pm
Carl Borrebaeck
Carl Borrebaeck brings experience from his time as a board member of Immunovia AB, SenzaGen AB, CB Ocean Capital AB, Alligator Bioscience AB, Clinical Laserthermia Systems AB, Scandion A/S, and commercial experience from a number of IPOs. He has a DSc in biochemistry with a focus on molecular immunology, is a professor and former Vice President at […]

Anneli Palm is new chairman of the board at Mercodia

15 October 2018 | 12:25 pm
Anneli Palm
Anneli Palm  has been a member of the board since 2009 and she will replace her father, Erling Holmlund, as chairman. Palm has since 2009 worked actively to pursue and structure the board’s work. She brings skills as an administrator and her passion for a strong and healthy company culture to the company, it states in […]

SenzaGen appoints US Business Development Director and establishes a wholly-owned subsidiary

12 October 2018 | 12:27 pm
The company is strengthening its presence in the US market through a recruitment of Dr. Joshua J. Schmidt as Business Development Director at SenzaGen Inc. The appointment represents a further expansion of the company’s commercial organization and an increasing focus on establishing collaborations with both licensees and distributors, in accordance with SenzaGen’s recently communicated financial […]

Acarix in strategic alliance with MED Management

12 October 2018 | 11:51 am
Acarix and MED Management are entering into an agreement for the German outpatient market. “The CADScor system is perfectly suited for supporting MED Management’s overall strategy of offering solutions to improve patient care, especially in the outpatient market. We see CADScor as an important contributor to our offering and we are looking forward to developing […]

Sinntaxis secures option on ex-AstraZeneca drug

11 October 2018 | 6:06 am
Sinntaxis has signed an option deal with Acturum regarding an exclusive license for the drug candidate AZD2066. The phase II ready molecule (mGluR5 antagonist) could enhance recovery of brain functions after stroke. It was first developed by AstraZeneca and has previously been studied in clinical phase II patients with neuropathic pain. The company now hopes […]

Improving the development of biopharmaceuticals in Finland

10 October 2018 | 2:51 pm
Petri dish
Researchers of organic chemistry and biotechnology from the University of Turku are creating new medical technologies in an Ecosystem coordinated by Orion Corporation. ​Together with selected university research groups and other companies, Orion Corporation has assembled a New Modalities Ecosystem supported by funding from Business Finland. One goal of the Ecosystem is to improve the […]

New results about immunotherapy in hereditary melanoma

10 October 2018 | 2:24 pm
Hildur Helgadottir
Researchers at Karolinska Institutet have examined how effective immunological checkpoint therapy is for individuals with inherited CDKN2A mutation and metastatic melanoma. In recent years, new immunological treatments have appeared that many melanoma patients respond well to. These, so called immune checkpoint inhibitors treat cancer by inhibiting brake mechanisms in the immune system, a discovery by […]

Medicine meets technology in Stavanger

10 October 2018 | 1:50 pm
Stavanger University Hospital
Norway’s Stavanger is a city with much to celebrate and even more to look forward to. The third largest city and metropolitan area in Norway, Stavanger has numerous energy and technology companies, as well as a major university and hospital. The city has a rich life science and research landscape, which only promises to grow […]

InfiCure collaborates with CSL

9 October 2018 | 9:12 am
Dan Holmberg and Sofia Mayans Inficure
The Umeå based company InfiCure Bio has signed a contract for global collaboration with the global biotech company CSL. The two companies will test CSL’s experimental anti-fibrotic reagent in the N-IF mouse, InfiCure’s model for fibrosis. The management team of InfiCure Bio believes that the N-IF mouse will become an important player in the field […]